About this opportunity
AI summaryThe US Food and Drug Administration solicits basic and applied research and development proposals to advance regulatory science and innovation. This acquisition supports the agency's mission to protect and promote public health through extramural research across designated research areas and sub-areas of interest. Applicants must prepare a Statement of Work detailing the general scope, chronological contractor requirements using mandatory terms, and deliverable items such as technical and financial progress reports, final reports, software, or hardware. Offerors must submit proposals by 5:00 pm on January 22, 2027.
Federal notice details
- Solicitation number
- FDABAA-27-00123
- Agency
- Department of Health and Human Services
- Buying office
- Food and Drug Administration › FDA Office of ACQ Grant SVCS
- Notice type
- Special Notice
- Responses due
- Jan 22, 2027, 5:00 PM ET
- Posted on SAM.gov
- Oct 30, 2026
- NAICS
- 541714 · Research and Development in Biotechnology (except Nanobiotechnology)
- Product/service code
- AJ11
- Set-aside
- No Set aside used
- Contracting contact
- Ian Weiss
Ian.Weiss@fda.hhs.gov
3017965728
Source: SAM.gov. Read the official notice for the complete description and current instructions.
Incumbent and award research
No incumbent history found for this requirement. The notice does not cite a current contract, and no earlier award from this buying office matches it.
Market context
Awards in the same category (Research and Development in Biotechnology (except Nanobiotechnology)). This is not this requirement's award history.
Recent similar awards: Department of Health and Human Services, NAICS 541714
| Vendor and award | Value | Ends |
|---|---|---|
| AMGEN USA INC75A50122C00065 · TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MA | $839.9M | Sep 29, 2032 |
| 4J THERAPEUTICS INC75A50124C00052 · THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF O | $63.1M | Mar 31, 2032 |
| BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL75A50124C00033 · THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFE | $122.5M | Mar 31, 2032 |
| SRI INTERNATIONAL75N93026F00002 · TO AWARD TASK ORDER C03 | $722.0K | Feb 19, 2032 |
| ADVANCED TECHNOLOGY INTERNATIONAL75A50123F61002 · OT TASK ORDER 2 | $129.1M | Jan 31, 2032 |
Top vendors in this category: Department of Health and Human Services, NAICS 541714, since Oct 1, 2024
1,143 contract awards in this NAICS over the period.
- 1. ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE)$336.6M
- 2. AMGEN USA INC$215.9M
- 3. START2 GROUP, INC.$194.3M
- 4. SHIONOGI INC$156.1M
- 5. MAPP BIOPHARMACEUTICAL, INC.$133.1M
Source: USAspending.gov federal award data (U.S. federal public data). A contract is called the incumbent only when the notice or its documents cite it by number.